Evidence map›Paper›PMID 42730173›Full record

ArticleWorld journal of oncology2026

Tumor Marker Heterogeneity in Ovarian Cancer: Clinical Implications of Pretreatment Monitoring of Serum Biomarkers for Recurrence Prediction.

Ahmad Alwazzan, Ahmad Badeghiesh, Majid Almansouri, Dahlia Mirdad, Razan Amjad, Zayd Jastaniah, Huda Altoukhi, Rayyan Hasanain, Abdulkareem Fayoumi, Hatim Almarzouki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmad AlwazzanDepartment of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0001-9355-5483
Ahmad BadeghieshDepartment of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Majid AlmansouriDepartment of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Dahlia MirdadDepartment of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Razan AmjadDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Zayd JastaniahDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Huda AltoukhiDepartment of Radiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Rayyan HasanainDepartment of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdulkareem FayoumiDepartment of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Hatim AlmarzoukiDepartment of Radiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovarian cancer remains a highly lethal gynecological malignancy with heterogeneous clinical outcomes. Reliable pretreatment biomarkers are needed to improve prognostic stratification. This study aimed to evaluate variations in pretreatment serum cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), and lactate dehydrogenase (LDH) across ovarian cancer subtypes and to determine their ability to predict time to recurrence after treatment. Methods: This retrospective cohort study included adult patients with histologically confirmed ovarian cancer treated with cytoreductive surgery and adjuvant chemotherapy. Pretreatment serum CA-125, CEA, and LDH levels were measured using standardized immunoassays. Biomarker distributions were analyzed by tumor subtype, and time to recurrence after treatment was assessed using Cox proportional hazards regression analysis and Kaplan-Meier analysis. Results: The study included 126 ovarian cancer patients (mean age 53.17 ± 15.47 years). Serous carcinoma was most common (46%), with most patients presenting at advanced stage IIIb (44.4%) and 57% having high-grade tumors. Elevated pretreatment CA-125 was observed in 76.7%, while CEA and LDH were less frequent (13.3% and 11.7%). Kaplan-Meier analysis showed that elevated CA-125 was associated with a longer time to recurrence after treatment (log-rank P = 0.0057), whereas CEA (P = 0.853) and LDH (P = 0.562) did not show a statistically significant association. In multivariable Cox proportional hazards regression analysis, LDH was independently associated with a shorter time-to-event (hazard ratio (HR), 1.92; 95% CI, 1.03-3.56; P = 0.039), while CEA showed a modest association (HR, 0.50; 95% CI, 0.25-0.98; P = 0.043). CA-125 did not show a statistically significant association (HR, 0.64; P = 0.072). Suboptimal surgery predicted worse outcomes (HR, 4.79; P < 0.001). Conclusions: Pretreatment serum CA-125 was not independently associated with time to recurrence after adjustment. Elevated LDH was associated with shorter time-to-event, whereas the prognostic significance of CEA remained uncertain and should be interpreted cautiously. Suboptimal surgical cytoreduction remained strongly associated with worse outcomes. These findings suggest LDH may have prognostic relevance, whereas CA-125 and CEA have limited independent value in this cohort.

Indexed as

CA-125Carcinoembryonic antigenLactate dehydrogenaseOvarian cancerPretreatment biomarkersPrognosis

Identifiers

PMID42730173
PMCPMC13568730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.